A randomised, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalised Anxiety Disorder (GAD).

Trial Profile

A randomised, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalised Anxiety Disorder (GAD).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Acronyms 2BMC1
  • Most Recent Events

    • 20 Apr 2015 According to Bionomics media release, the results are expected in third quarter of 2016.
    • 20 Apr 2015 According to Bionomics media release, status changed from planning to recruiting.
    • 13 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top